Prescription drugs sales at 340B prices were $38.8 billion in 2020, “more than three times the level of 340B sales compared to just five years prior,” new drug industry funded research shows.
Total sales would have been $93.6 billion if drug manufacturers could have charged covered entities wholesale prices instead of 340B ceiling prices, according to the June 30 report by Berkeley Research Group funded by Pharmaceutical Research and Manufacturers of America.
Prescription drugs sales at 340B prices were $38.8 billion in 2020, “more than three times the level of 340B sales compared to just five years prior,” new drug industry funded research shows.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
